Zuprevo Rx 100 mL

Zuprevo 18% (Tildipirosin) is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in beef and non-lactating dairy cattle, and for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. See package insert for complete product details. For the treatment and prevention of BRD associated with M. haemolytica, P. multocida and H.somni sensitive to Tildipirosin. Offers a distinctive combination of performance properties. Has a prolonged concentration in lung tissue and in bronchial fluids, and it has rapid absorption in the system.

A macrolide antibiotic that is absorbed quickly from the injection site and reaches peak plasma concentrations within 23 minutes; faster than comparable macrolide products. It also persists in the lungs for up to 28 days; 7 days longer than other long-acting products. Indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia Haemolytica, Pasteurella multocida, and Histophilus somni (formerly Haemophilus somnus). For the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni.

Dosage: For subcutaneous injection in beef and non-lactating dairy cattle only. Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal. 21-day withdrawal. Cattle: 1ml/100lbs body weight.

Zuprevo - Rx 100 mL Highlights:

• SKU: 17454
• Manufacturer: Merck Animal Health
• Fast-acting antibiotic reaches peak concentrations in as little as 23 minutes.
• Low volume dosage means less injection site reactions and tissue damage.
• Administer 4 mg tildipirosin/kg body weight (equivalent to 1 ml/45 kg body weight) once only.
• For treatment of cattle over 450 kg body weight, divide the dose so that no more than 10 ml are injected at one site.
• The rubber stopper of the vial may be safely punctured up to 20 times. Otherwise, the use of a multiple-dose syringe is recommended.
• To ensure correct dosage, bodyweight should be determined as accurately as possible to avoid underdosing.
• It is recommended to treat animals in the early stages of the disease and to evaluate the response to treatment within 2 to 3 days after injection.
• If clinical signs of respiratory disease persist or increase, treatment should be changed using another antibiotic, and continued until clinical signs have resolved.
• Long lasting product stays at treatment levels in the lungs for up to 28 days meaning less stress, lower treatment costs, and reduced labor.